Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138733 · ClinicalTrials.gov registry record · Phase 3
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
A Phase 3 study, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT03138733 is a Phase 3 study that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 390 participants.
The verdict
NCT03138733, a Phase 3 study, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
Interventions
- DRUG Daptomycin
- DRUG Ceftobiprole medocaril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2018-08-26 |
| Est. Completion | 2022-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138733
The ClinicalTrials.gov registry entry for NCT03138733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Daptomycin is the first listed.
NCT03138733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138733 about?
NCT03138733 is a clinical study titled "Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia". The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
What is the current status of trial NCT03138733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2018-08-26. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT03138733?
The interventions under investigation include: Daptomycin (DRUG), Ceftobiprole medocaril (DRUG).
Who is sponsoring clinical trial NCT03138733?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.